Beta
ManageSearchChatDiscover
235909

Cyclophosphamide-induced cardiotoxicity

Article

Last updated: 27 Dec 2024

OverviewSimilar Items

Subjects

-

Tags

-

Abstract

One of the commonest antitumor drugs is cyclophosphamide (CP). CP that is used in management of many tumors and autoimmune disease as well as in polychemotherapy regimens and immunosuppressive protocols. It doesn't only have a specific effect on cancer cells, but also it produces many toxic effects. One of the most important side effects of CP that limits its use in clinical practice is its dose dependent toxicity on the heart. The incidence of cardiotoxicity at doses over 120-150 mg/kg is of 8-20% in adults, and 5% in children. The incidence of heart failure after high doses of CP varies widely from author to author: less than 5% and 10-29%.This review article discusses the molecular mechanism of CP cardiotoxicity with some of different signaling pathways that contribute in the development of such toxicity. Our main concern from discussing these molecular mechanisms of CP induced cardiotoxicity is to help in development of new therapies.

DOI

10.21608/aijpms.2022.114213.1103

Keywords

cyclophosphamide, Anti-neoplastic, cardiotoxicity, Signaling pathways, Molecular mechanism

Authors

First Name

Somow

Last Name

Kamel

MiddleName

S

Affiliation

Pharmacology and Toxicology Department, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt.

Email

somowsamy@gmail.com

City

-

Orcid

-

First Name

Nayira

Last Name

Abdelbaky

MiddleName

A.

Affiliation

Pharmacology and Toxicology Department, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt.

Email

nayiraabdelbaky@yahoo.com

City

Cairo

Orcid

/0000-0002-6175-184X

First Name

Mohammed

Last Name

Sayed-Ahmed

MiddleName

M

Affiliation

Pharmacology and Experimental Oncology Unit, National Cancer Institute, Cairo University, Cairo, Egypt.

Email

sayedahmedmm@hotmail.com

City

-

Orcid

-

First Name

Riham

Last Name

Karkeet

MiddleName

M

Affiliation

Pharmacology and Experimental Oncology Unit, National Cancer Institute, Cairo University, Cairo, Egypt.

Email

riham.karkeet@nci.cu.edu.eg

City

-

Orcid

-

First Name

Abdel-Moneim

Last Name

Osman

MiddleName

M

Affiliation

Pharmacology and Experimental Oncology Unit, National Cancer Institute, Cairo University, Cairo, Egypt.

Email

moneimosman@hotmail.com

City

-

Orcid

-

First Name

Mariam

Last Name

Fouad

MiddleName

A

Affiliation

Pharmacology and Experimental Oncology Unit, National Cancer Institute, Cairo University, Cairo, Egypt., Molecular and Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA.

Email

mariam.fouad@nci.cu.edu.eg

City

-

Orcid

-

Volume

2

Article Issue

2

Related Issue

34881

Issue Date

2022-06-01

Receive Date

2022-01-02

Publish Date

2022-06-01

Page Start

1

Page End

8

Print ISSN

2735-4598

Online ISSN

2735-4601

Article File

AIJPMS_Volume 2_Issue 2_Pages 1-8.pdf

PDF . 330.1kB

Link

https://aijpms.journals.ekb.eg/article_235909.html

Detail API

https://aijpms.journals.ekb.eg/service?article_code=235909

Order

1

Type

Review Articles

Type Code

1,563

Publication Type

Journal

Publication Title

Azhar International Journal of Pharmaceutical and Medical Sciences

Publication Link

https://aijpms.journals.ekb.eg/

MainTitle

Cyclophosphamide-induced cardiotoxicity

Details

Type

Article

Created At

23 Jan 2023